References
- Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–849.
- Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25.
- Menter T, Schlageter M, Bastian L, et al. Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia. Hematol Oncol. 2014;32:47–51.
- Gaulier A, Jary-Bourguignat L, Serna R, et al. Occurrence of angioimmunoblastic T cell lymphoma in a patient with chronic myelomonocytic leukemia features. Leuk Lymphoma. 2000;40:197–204.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Research Data, Nov 2014 Sub (1992-2012) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.
- El-Fattah MA. Clinical prognostic factors and survival outcome of chronic myelomonocytic leukemia: reviewing 3,686 patients. Clin Lymphoma Myeloma Leuk. 2016;16:e119–e121.
- Grignano E, Mekinian A, Braun T, et al. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leuk Res. 2016;47:136–141.
- Patnaik MM, Wassie EA, Lasho TL, et al. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90:411–416.
- Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006;155:645–653.
- Ballerini P, Struski S, Cresson C, et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia. 2012;26:2384–2389.
- Adair A, Parker J, Coombes DS. Chronic myelomonocytic leukaemia (CMML) presenting as a thyroid mass. Br J Haematol. 2003;120:548.
- Peker D, Padron E, Bennett JM, et al. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015;133:249–256.
- Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51–60.
- Cunha LL, Ferreira RC, Marcello MA, et al. Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer. J Thyroid Res. 2011;2011:387062.
- Bartels Lehmann U, Büsche G, et al. Evolution of chronic myelomonocytic leukemia to myeloproliferative neoplasm. Ann Hematol. 2016;95:1377–1380.
- Tang G, Fu B, Hu S, et al. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015;90:882–887.
- Mathew RA, Bennett JM, Liu JJ, et al. Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012;36:72–80.